

CHINA MEDICAL (INTERNATIONAL) GROUP LIMITED

(Company Registration No. 200505118M)

PROPOSED RENOUNCEABLE AND NON-UNDERWRITTEN RIGHTS CUM WARRANTS ISSUE – RECEIPT OF LISTING AND QUOTATION NOTICE FOR ADDITIONAL OUTSTANDING WARRANTS AND ADDITIONAL NEW SHARES

The Board of Directors (“**Directors**”) of China Medical (International) Group Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) refers to the announcements made by the Company on 31 March 2017, 7 June 2017, 18 September 2017, 25 September 2017, 3 October 2017, 11 October 2017 and 13 October (the “**Previous Announcements**”) in relation to:

- (a) the proposed renounceable and non-underwritten rights issue of up to 10,107,788,721 new ordinary shares of the Company (the “**Rights Shares**”) with up to 10,107,788,721 free detachable warrants (the “**Warrants**”), on the basis of three (3) Rights Shares for every one (1) existing ordinary share (the “**Shares**”) of the Company held by entitled shareholders as at the books closure date to be determined, and one (1) Warrant for every one (1) Rights Shares subscribed, fractional entitlements to be disregarded (the “**Rights cum Warrants Issue**”); and
- (b) the Adjustments.

Unless otherwise defined, all capitalised terms used herein shall bear the same meanings as ascribed to them in the Previous Announcements.

The Directors wish to announce that the Company’s Sponsor (as defined below) has, on 20 October 2017, obtained the listing and quotation notice (the “**LQN**”) from the SGX-ST in respect of the listing and quotation of:

- (a) up to 106,198,391 Additional Outstanding Warrants; and
- (b) up to 106,198,391 Additional New Shares,

on SGX-ST Catalist, subject to compliance with the listing requirements of the SGX-ST.

Please note that the LQN is not an indication of the merits of the Warrants Adjustment, Additional Outstanding Warrants, Additional New Shares, the Company, its subsidiaries and their securities.

By Order of the Board
21 October 2017

*This announcement has been prepared by the Company and its contents have been reviewed by the Company’s sponsor, PrimePartners Corporate Finance Pte. Ltd. (the “**Sponsor**”) for compliance with the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement.*

This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Lance Tan, Director, Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).